News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
10 July 2026

Tanzania SGR: An ECA coordination feat

Tanzania’s latest standard gauge railway financing shows that African transport corridors can access global liquidity. But only when sovereign risk, export credit, MDB...

Video
14 July 2026

Uncertainty is the unwelcome gift, but pipeline grows for...

Speaking at TXF Global, Jebsen & Jessen CEO Ralf Schwarzhaupt highlighted a booming project pipeline despite Middle East headwinds, calling for fewer regulations, faster...